Type
1.
Pam D, Souza D, D’Souza S, Opoku M, Sanda S, Nazaradden I, et al. Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria. PLoS neglected tropical diseases [Internet]. 2017;11(10):e0006004. Available from: http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0006004&type=printable
Type
1.
Streit T, Lafontant JG, Direny A, Addiss D, Milord MD 8Health and Development International, Newburyport, Massachusetts;, Lammie P, et al. Translating research into reality: Elimination of lymphatic filariasis from Haiti. The American journal of tropical medicine and hygiene [Internet]. 2017;97(4_Suppl):71–75. Available from: http://www.ajtmh.org/docserver/fulltext/14761645/97/4_Suppl/tpmd160669.pdf?expires=1508839073&id=id&accname=guest&checksum=5B58BDFAE9F5311FA5E72B7F88FB6E0B
Type
1.
Horstick O, Runge-Ranzinger S. Protection of the house against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis: a systematic review. The Lancet. Infectious diseases. 2017;
Type
1.
Koroma. Preventive chemotherapy for elimination of lymphatic filariasis and onchocerciasis in Sierra Leone. Vol. Doctoral, University of Liverpool . 2017.
Type
1.
World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2016. Weekly epidemiological record [Internet]. 2017;92(40):594-608. Available from: http://apps.who.int/iris/bitstream/10665/259184/1/WER9240.pdf?ua=1
Type
1.
Shrivastava S, Shrivastava P, Ramasamy J. Elimination target for lymphatic filariasis attained in Sri Lanka and Maldives: World health organization. Annals of tropical medicine and public health [Internet]. 2017;10(5):1369-70. Available from: http://www.atmph.org/article.asp?issn=1755-6783;year=2017;volume=10;issue=5;spage=1369;epage=1370;aulast=Shrivastava
Type
Notes
<p>People with disabilities are often not able to have a say in decisions that are made that affect them, including in the way that international development is organised, and research is carried out. <a class="ext" href="http://www.cbm.org/" target="_blank">CBM</a> is committed to challenging this situation, believing that people affected by such decisions should have a voice in them, and that they hold a unique form of expertise that can contribute to excellence in research and programming.</p>
Custom 7
<div>
<div>
<div>
<div>
<div>
<div>
<div>Julian Eaton and Muhammad Jidda Assakin</div>
</div>
</div>
</div>
</div>
</div>
</div>
Year of Publication
2017
Publication Language
eng
Citation Key
30828
Type
1.
Brant T, Okorie P, Ogunmola O, Ojeyode NB, Fatunade, Davies E Federal Ministry of Health, et al. Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. Parasite epidemiology and control [Internet]. 2018;3(1):21–35. Available from: https://tinyurl.com/ybnnnh8u
Type
1.
Saha S, Miah KA, Alam A, Haque HS, Sultana S, Haque N, et al. Operational issues of lymphatic filariasis elimination program and community acceptance of mass drug administration. Chattagram International Medical College Journal [Internet]. 2016;1(1):7-11. Available from: http://cimch.edu.bd/resources/journal/Article-2.pdf
Type
1.
Hettrick. Establishing a lymphatic filariasis morbidity plan for Haiti. Wound practice and research [Internet]. 2017;25(3):146-8. Available from: http://www.woundsaustralia.com.au/journal/2503_05.pdf